English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Rapid development of modern areas of biomedical science contributes to the increase of the implementation rate, of innovative products and services in medicine, in particular, clinical oncology. The purpose of the article is the comparative analysis of the experience of R&amp;D results commercialization in biomedical sector of the developed countries and Ukraine. The study uses methods of structural and logical analysis and comparative content analysis. Commercialization fits the inventor interests in using intellectual property, provides its implementation, and reveals commercial advantages to continue scientific and innovative activity. Society is interested in successful commercialization and technology transfer in biomedical field that increase competitiveness level of health system. Such activity stimulates scientists to develop innovative products. In foreign countries, legal and organizational mechanisms have been created that stimulate of investment activities for conducting research in the biomedical science at universities and scientific institutions. The development of links in the field of commercialization of R&amp;D results has become a priority of the innovation policy of many countries, and public-private partnerships are an effective tool for its implementation, as evidenced by the rising of national budgets, legislative initiatives and the development of new programs. The analysis of the foreign experience of technology transfer of medical and biological R&amp;D results allows to highlight several points: the financial support of research institutes and universities is considered as an important function of the state; public financing of projects in the field of medicine and biology is carried out within a quite long period of time (often not less than10 years), and the purchase of equipment is not a central item of expenditures; assessment of the productivity of researchers is complemented by evaluating the performance of the departments responsible for research management and funding; quantitative indicators of research unit results are supplemented by expert assessments of the quality of research, effectiveness and safety of medical developments based on new knowledge and achievements of scientific and technological progress. Conclusion. In Ukraine, despite certain difficulties in recent years, the high scientific potential in the field of biomedical sciences provides an increase of the number of high-tech innovative scientific and technological developments. Taking into account the low innovative activity of scientific institutions and universities, commercialization requires a systematic state approach, the development of strategies, specific mechanisms, methods and forms

Commercialization Capability of R&D Results in Biomedical Field of Ukraine and Analysis of Related Foreign Experience